WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis.
“We wanted to identify if we could predict response to treatment among patients treated with resmetirom,” Rohit Loomba, MD, MHSc, professor of medicine and chief of the division of gastroenterology and hepatology at University of California, San Diego, School of Medicine and director of the MASLD Research Center, told Healio. “This will be helpful to